ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO559

Machine Perfusion of Mice Kidneys to Deliver a Protective Bioengineered Soluble ACE2 Protein

Session Information

  • Bioengineering
    October 26, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bioengineering

  • 400 Bioengineering

Authors

  • Cianfarini, Cosimo, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Yamani, Fatmah Najeeb, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Wysocki, Jan, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Jaishankar, Dinesh, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Zhang, Zheng Jenny, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Batlle, Daniel, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Background

Machine perfusion of donor kidneys has emerged as a promising approach to improve transplant outcomes by decreasing storage-related injury and reducing the occurrence of delayed graft function (DGF). Activation of the renin-angiotensin-system (RAS) has been shown to play a role in the pathophysiology of DGF and countering this overactivity may improve transplant outcomes. Here we investigated the delivery of a short soluble ACE2 protein, bioengineered in our lab and termed ACE2-618-ABD, to mice kidneys using hypothermic machine perfusion as a strategy to reduce RAS activity.

Methods

Kidneys from c57bl6 ACE2 Knock-Out (ACE2-KO) and c57bl6 wildtype (WT) mice were harvested and the renal artery cannulated. We adapted a perfusion system previously used for rats to be used with mice kidneys. The mice kidneys were perfused with phosphate buffered saline (PBS) either alone or with added ACE2 618-ABD for four hours at four degrees celsius through the cannulated renal artery in a closed-circuit perfusion system using a peristaltic pump. ACE2 enzymatic activity was then measured using a fluorogenic assay and ACE2 protein levels determined by Western Blot.

Results

While ACE2 enzymatic activity and protein were undetectable in non-perfused ACE2-KO kidneys, enzymatic activity and protein by Western Blot were found in ACE2-618-ABD perfused ACE2-KO kidneys. In WT kidneys perfused with ACE2-618-ABD, Western Blot showed two distinct bands for ACE2 protein at ~100kD and ~85kD. The ~100kD band reflects the native ACE2, the ~85kD represents the perfused short soluble ACE2-618-ABD which was not found in the PBS- and non-perfused WT kidneys. In kidney lysates, the cytosolic compartment of ACE2-618-ABD perfused kidneys had increased ACE2 enzymatic activity and protein demonstrating intracellular uptake.

Conclusion

Delivery of a bioengineered, short soluble ACE2 protein to mice kidneys can be accomplished via machine perfusion of the renal artery which results in passage of the glomerular filtration barrier and tubular uptake. Ex-vivo perfusion of kidneys with ACE2-618-ABD results in cytosolic uptake as demonstrated by increased protein and enzymatic activity. This approach may result in improved quality of kidneys prior to transplantation.

Funding

  • Other NIH Support